On March 27, 2018 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported that Charles D. Kaplan, Director of Immuno-Oncology Research at Five Prime, has been invited to give an oral presentation at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 14 – 18, 2018, in Chicago (Press release, Five Prime Therapeutics, MAR 27, 2018, View Source [SID1234525010]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Title: FPA150: A recombinant, afucosylated, fully human IgG1 monoclonal antibody for the treatment of malignancies that express high levels of B7-H4
Presenter Name: Charles D. Kaplan
Session Type: Drug Development Track – Special Session
Session Title: New Drugs on the Horizon 1
Session Start Time: April 15, 20181:00 PM
Location: Room S103 – McCormick Place South (Level 1)
About FPA150
FPA150 is a novel, fully human, afucosylated monoclonal antibody targeting B7-H4. B7-H4 expression is observed in multiple solid tumors, including breast, bladder and gynecologic cancers, and has been documented to correlate with poor prognosis. FPA150 is designed with a dual mechanism of action: blocking the T cell checkpoint activity of B7-H4 as well as delivering potent antibody-dependent cell-mediated cytotoxicity against tumor cells expressing B7-H4. Five Prime anticipates initiating Phase 1 development of FPA150 during the first half of 2018.